Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-04-30
2008-12-09
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S091310, C435S320100, C435S455000, C536S023100, C536S024500
Reexamination Certificate
active
07462602
ABSTRACT:
Methods and compositions for treating scarring conditions associated with increased expression of connective tissue growth factor (CTGF). Aspects of the invention include ribozymes that cleave mRNA targets required for CTGF expression, cells containing anti-CTGF ribozymes and vectored anti-CTGF ribozymes suitable for delivery to cellular targets capable of CTGF expression.
REFERENCES:
patent: 5770209 (1998-06-01), Grotendorst et al.
patent: 7026299 (2006-04-01), Li et al.
patent: 7108982 (2006-09-01), Hageman
patent: 2003/0180891 (2003-09-01), Young et al.
patent: 2004/0005319 (2004-01-01), Grotendorst et al.
patent: WO 01/64946 (2001-09-01), None
Opalinska, J. B. et al., Nature Reviews, vol. 1, pp. 503-514 (2002).
Crooke, S.T., Antisense Research & Application, Chapter 1, pp. 1-50 (Ed. by S. Crooke). Springer-Verlag (1998).
Chirila, T.V. et al. Biomaterials vol. 23, pp. 321-342 (2002).
Peracchi, A. Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Branch, A.D., Trends in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Yuan, R. et al., Wound Repair & Regeneration, vol. 9, No. 2, p. 154 (Abstract No. 63) (Mar.-Apr. 2001).
Bai et al. Multivalent Anti-CCR5 Ribozymes for Stem Cell-Based HIV Type 1 Gene Therapy. AIDS Research and Human Retroviruses. 2001, vol. 17, No. 5, pp. 385-399.
Fritz et al. Development of Hammerhead Ribozymes to Modulate Endogenous Gene Expression for Functional Studies. Methods. 2002, vol. 28, pp. 276-285.
Fritz et al. [21] Designating and Characterizing Hammerhead Ribozymes for Use in AAV Vector-Mediated Retinal Gene Therapies. Methods in Enzymology. 2002, vol. 346, pp. 358-377.
Lewin et al. Ribozyme Gene Therapy: Applications for Molecular Medicine. Trends in Molecular Medicine. 2001, vol. 7, No. 5, pp. 221-228.
O'Neill et al. Ribozyme-Based Therapeutic Approaches for Autosomal Dominant Retinitis Pigmentosa. Investigative Ophthalmology & Visual Science. 2000, vol. 41, No. 10, pp. 2863-2869.
Qi et al. Optic Neuropathy Induced by Reductions in Mitochondrial Superoxide Dismutase. Investigative Ophthalmology & Visual Science. 2003, vol. 44, No. 3, pp. 1088-1096.
Qi et al. Suppression of Complex I Gene Expression Induces Optic Neuropathy. Optic Neuropathy. 2003, vol. 53, pp. 198-205.
Ramezani et al. Inhibition of HIV-1 Replication by Retroviral Vectors Expressing Monomeric and Multimeric Hammerhead Ribozymes. Gene Therapy. 1997, vol. 4, pp. 861-867.
Seyhan et al. Ribozyme Inhibition of Alphavirus Replication. The Journal of Biological Chemistry. 2002, vol. 277, No. 29, pp. 25957-25962.
Shaw et al. [49] Ribozymes in Treatment of Inherited Retinal Disease. Methods in Enzymology. 2000, vol. 316, pp. 761-776.
Shen et al. Multi-Ribozyme Targeting of Human Alpha-Globin Gene Expression. Blood Cells, Molecules and Diseases. 1999, vol. 25, No. 24, pp. 361-373.
Blalock Timothy D.
Lewin Alfred S.
Schultz Gregory S.
Beusse Wolter Sanks Mora & Maire
University of Florida Research Foundation Inc.
Van Dyke Timothy H.
Zara Jane
LandOfFree
Anti-scarring ribozymes and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-scarring ribozymes and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-scarring ribozymes and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4035291